Malamitsi J, Skarlos D, Fotiou S, Papakostas P, Aravantinos G, Vassilarou D, Taylor-Papadimitriou J, Koutoulidis K, Hooker G, Snook D
Nuclear Medicine Department, NIMTS, Athens, Greece.
J Nucl Med. 1988 Dec;29(12):1910-5.
Six patients with metastatic breast cancer and malignant pleural effusions and 13 patients with known or suspected ovarian cancer, underwent immunoscintigraphy after intracavitary (intrapleural or intraperitoneal) administration of iodine-131-(131I) or indium-111-(111In) labeled tumor associated monoclonal antibodies HMFG2 and H17E2. This method proved to be sensitive and specific with a true-positive result in 13 out of 14 patients with tumor and a true-negative result in five out of five patients without tumor. At any one time, 65%-80% of the whole-body radioactivity was closely associated with the cavity into which the radiolabeled antibody was administered while the radioactivity in the blood was always low, (approximately 4 X 10(-3) of administered dose/ml of blood). Concentrations of radiolabeled antibody (per gram of tumor tissue) ranged from 0.02%-0.1% of the injected dose in intracavitary tumors, but only 0.002% in a retroperitoneal metastasis. The specificity of this approach was documented in four control patients with benign ovarian cysts and in two patients who were imaged using both specific and nonspecific radiolabeled antibody. We conclude that the intracavitary administration of 131I- or 111In-labeled HMFG2 and H17E2 is a favorable route of administration and offers significant advantages over previously reported intravenous administration for the localization of breast or ovarian metastases confined to the pleural or peritoneal cavities.
6例转移性乳腺癌伴恶性胸腔积液患者和13例已知或疑似卵巢癌患者，在胸腔内（胸膜腔内或腹腔内）注射碘-131-（131I）或铟-111-（111In）标记的肿瘤相关单克隆抗体HMFG2和H17E2后接受免疫闪烁扫描。该方法被证明具有敏感性和特异性，14例有肿瘤的患者中有13例为真阳性结果，5例无肿瘤的患者中有5例为真阴性结果。在任何时候，全身放射性的65%-80%与注射放射性标记抗体的腔密切相关，而血液中的放射性始终较低（约为注射剂量的4×10⁻³/毫升血液）。放射性标记抗体（每克肿瘤组织）的浓度在胸腔内肿瘤中为注射剂量的0.02%-0.1%，但在腹膜后转移灶中仅为0.002%。4例良性卵巢囊肿对照患者以及2例同时使用特异性和非特异性放射性标记抗体成像的患者证明了该方法的特异性。我们得出结论，胸腔内注射131I或111In标记的HMFG2和H17E2是一种有利的给药途径，与先前报道的静脉给药相比，对于局限于胸膜腔或腹膜腔的乳腺或卵巢转移灶的定位具有显著优势。
